BIOCRYST PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Year Two
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Long-Term Debt, Maturity, Year Two of $20.00 million as of 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2020-11-06
- 2020-09-30: Long-Term Debt, Maturity, Year Two $20.00M.
- 2020-06-30: Long-Term Debt, Maturity, Year Two $20.00M.
- 2020-03-31: Long-Term Debt, Maturity, Year Two $20.00M.
- 2019-12-31: Long-Term Debt, Maturity, Year Two $20.00M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2020-09-30 | $20.00M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $20.00M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $20.00M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $20.00M 10-K · filed 2020-03-13 |
| 2019-09-30 | $10.00M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $10.00M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $10.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $12.00M 10-K · filed 2019-03-14 |
| 2018-09-30 | $5.00M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $6.90M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $6.90M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $6.90M 10-K · filed 2018-03-12 |
| 2017-09-30 | $6.90M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $6.90M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $6.90M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $6.90M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |